bumetanide has been researched along with Parkinson Disease, Secondary in 1 studies
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lozovaya, N | 1 |
| Eftekhari, S | 1 |
| Cloarec, R | 1 |
| Gouty-Colomer, LA | 1 |
| Dufour, A | 1 |
| Riffault, B | 1 |
| Billon-Grand, M | 1 |
| Pons-Bennaceur, A | 1 |
| Oumar, N | 1 |
| Burnashev, N | 1 |
| Ben-Ari, Y | 1 |
| Hammond, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease[NCT03899324] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-04-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for bumetanide and Parkinson Disease, Secondary
| Article | Year |
|---|---|
GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease.
Topics: Acetylcholine; Action Potentials; Animals; Bumetanide; Chlorides; Cholinergic Agents; Cholinergic Ne | 2018 |